After Merck Keytruda, BMS’s Opdivo showed very good results in a trial where it improves survival over chemotherapy. About 73% of melanoma patients receiving the Bristol-Myers drug, nivolumab, were still alive one year after the start of treatment, compared with 42% of those receiving chemotherapy dacarbazine, according to results published online by the New England Journal of Medicine and presented at the Congress in Zurich. It looks like immunotherapy now has centre stage in advanced melanoma treatment.
Have access to the original article published in the New England Journal of Medicine here.
